Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Mar. 31, 2020 | May 05, 2020 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q2 | |
Trading Symbol | ARWR | |
Entity Registrant Name | ARROWHEAD PHARMACEUTICALS, INC. | |
Entity Central Index Key | 0000879407 | |
Entity Current Reporting Status | Yes | |
Current Fiscal Year End Date | --09-30 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 101,773,274 | |
Entity Shell Company | false | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity File Number | 001-38042 | |
Entity Tax Identification Number | 46-0408024 | |
Entity Address, Address Line One | 177 E. Colorado Blvd | |
Entity Address, Address Line Two | Suite 700 | |
Entity Address, City or Town | Pasadena | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 91105 | |
City Area Code | 626 | |
Local Phone Number | 304-3400 | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Title of 12(b) Security | Common Stock, Par Value $0.001 per share | |
Security Exchange Name | NASDAQ | |
Entity Incorporation, State or Country Code | DE | |
Entity Interactive Data Current | Yes |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Mar. 31, 2020 | Sep. 30, 2019 |
CURRENT ASSETS | ||
Cash and cash equivalents | $ 256,650,727 | $ 221,804,128 |
Accounts receivable | 1,265,771 | 661,361 |
Prepaid expenses | 3,062,333 | 3,317,999 |
Other current assets | 2,536,284 | 2,563,435 |
Short term investments | 50,959,058 | 36,899,894 |
TOTAL CURRENT ASSETS | 314,474,173 | 265,246,817 |
Property and equipment, net | 29,362,741 | 23,214,899 |
Intangible assets, net | 16,213,366 | 17,063,580 |
Long term investments | 190,618,075 | 44,175,993 |
Right-of-use assets | 10,263,197 | |
Other assets | 144,150 | 144,148 |
TOTAL ASSETS | 561,075,702 | 349,845,437 |
CURRENT LIABILITIES | ||
Accounts payable | 13,417,692 | 7,649,921 |
Accrued expenses | 4,419,233 | 6,504,729 |
Accrued payroll and benefits | 1,616,090 | 4,955,887 |
Lease liabilities | 688,454 | |
Deferred rent | 173,952 | |
Deferred revenue | 33,174,765 | 77,769,629 |
Other current liabilities | 17,263 | 16,561 |
TOTAL CURRENT LIABILITIES | 53,333,497 | 97,070,679 |
LONG-TERM LIABILITIES | ||
Lease liabilities, net of current portion | 14,178,735 | |
Deferred rent, net of current portion | 3,703,364 | |
Deferred revenue, net of current portion | 5,035,142 | |
TOTAL LONG-TERM LIABILITIES | 14,178,735 | 8,738,506 |
Commitments and contingencies (Note 7) | ||
Arrowhead Pharmaceuticals, Inc. stockholders' equity: | ||
Common stock, $0.001 par value; 145,000,000 shares authorized; 101,748,107 and 95,506,271 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively | 194,117 | 187,876 |
Additional paid-in capital | 936,353,920 | 664,086,155 |
Accumulated other comprehensive income (loss) | (629,114) | (391,624) |
Accumulated deficit | (441,800,265) | (419,290,967) |
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity | 494,118,658 | 244,591,440 |
Noncontrolling interest | (555,188) | (555,188) |
TOTAL STOCKHOLDERS’ EQUITY | 493,563,470 | 244,036,252 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 561,075,702 | $ 349,845,437 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2020 | Sep. 30, 2019 |
Statement Of Financial Position [Abstract] | ||
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 145,000,000 | 145,000,000 |
Common stock, shares issued | 101,748,107 | 95,506,271 |
Common stock, shares outstanding | 101,748,107 | 95,506,271 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | |
Income Statement [Abstract] | ||||
REVENUE | $ 23,528,853 | $ 48,148,275 | $ 52,983,433 | $ 82,806,171 |
Type of Revenue [Extensible List] | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember |
OPERATING EXPENSES | ||||
Research and development | $ 29,443,335 | $ 20,798,628 | $ 52,816,951 | $ 38,370,671 |
General and administrative expenses | 16,325,773 | 5,338,955 | 27,260,330 | 11,478,664 |
TOTAL OPERATING EXPENSES | 45,769,108 | 26,137,583 | 80,077,281 | 49,849,335 |
OPERATING INCOME (LOSS) | (22,240,255) | 22,010,692 | (27,093,848) | 32,956,836 |
OTHER INCOME (EXPENSE) | ||||
Interest income (expense), net | 2,404,685 | 1,886,290 | 4,584,550 | 2,977,399 |
TOTAL OTHER INCOME (EXPENSE) | 2,404,685 | 1,886,290 | 4,584,550 | 2,977,399 |
INCOME (LOSS) BEFORE INCOME TAXES | (19,835,570) | 23,896,982 | (22,509,298) | 35,934,235 |
NET INCOME (LOSS) | $ (19,835,570) | $ 23,896,982 | $ (22,509,298) | $ 35,934,235 |
NET INCOME (LOSS) PER SHARE - BASIC | $ (0.20) | $ 0.25 | $ (0.23) | $ 0.39 |
NET INCOME (LOSS) PER SHARE - DILUTED | $ (0.20) | $ 0.24 | $ (0.23) | $ 0.37 |
Weighted average shares outstanding - basic | 101,653,136 | 94,155,407 | 99,359,140 | 92,623,615 |
Weighted average shares outstanding - diluted | 101,653,136 | 98,082,644 | 99,359,140 | 97,214,546 |
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX: | ||||
Foreign currency translation adjustments | $ (433,564) | $ (28,162) | $ (237,490) | $ (50,342) |
COMPREHENSIVE INCOME (LOSS) | $ (20,269,134) | $ 23,868,820 | $ (22,746,788) | $ 35,883,893 |
Consolidated Statement of Stock
Consolidated Statement of Stockholders' Equity (unaudited) - USD ($) | Total | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit | Non-controlling Interest |
Beginning Balance, Amount at Sep. 30, 2018 | $ 95,241,001 | $ 180,875 | $ 582,902,694 | $ (21,564) | $ (487,265,816) | $ (555,188) |
Beginning Balance, Shares at Sep. 30, 2018 | 88,505,302 | |||||
Stock-based compensation | 5,318,882 | 5,318,882 | ||||
Exercise of stock options, Amount | 3,674,731 | $ 702 | 3,674,029 | |||
Exercise of stock options, Shares | 702,242 | |||||
Common stock - restricted stock units vesting, Amount | $ 2,197 | (2,197) | ||||
Common stock - restricted stock units vesting, Shares | 2,197,305 | |||||
Common stock - issued for cash, Amount | 60,521,729 | $ 3,261 | 60,518,468 | |||
Common stock - issued for cash, Shares | 3,260,869 | |||||
Foreign currency translation adjustments | (50,342) | (50,342) | ||||
Net income (loss) | 35,934,235 | 35,934,235 | ||||
Ending Balance, Amount at Mar. 31, 2019 | 200,640,236 | $ 187,035 | 652,411,876 | (71,906) | (451,331,581) | (555,188) |
Ending Balance, Shares at Mar. 31, 2019 | 94,665,718 | |||||
Beginning Balance, Amount at Dec. 31, 2018 | 171,500,031 | $ 184,961 | 647,142,565 | (43,744) | (475,228,563) | (555,188) |
Beginning Balance, Shares at Dec. 31, 2018 | 92,591,457 | |||||
Stock-based compensation | 2,601,348 | 2,601,348 | ||||
Exercise of stock options, Amount | 2,670,037 | $ 536 | 2,669,501 | |||
Exercise of stock options, Shares | 535,915 | |||||
Common stock - restricted stock units vesting, Amount | $ 1,538 | (1,538) | ||||
Common stock - restricted stock units vesting, Shares | 1,538,346 | |||||
Foreign currency translation adjustments | (28,162) | (28,162) | ||||
Net income (loss) | 23,896,982 | 23,896,982 | ||||
Ending Balance, Amount at Mar. 31, 2019 | 200,640,236 | $ 187,035 | 652,411,876 | (71,906) | (451,331,581) | (555,188) |
Ending Balance, Shares at Mar. 31, 2019 | 94,665,718 | |||||
Beginning Balance, Amount at Sep. 30, 2019 | 244,036,252 | $ 187,876 | 664,086,155 | (391,624) | (419,290,967) | (555,188) |
Beginning Balance, Shares at Sep. 30, 2019 | 95,506,271 | |||||
Stock-based compensation | 17,463,455 | 17,463,455 | ||||
Exercise of stock options, Amount | $ 4,331,577 | $ 686 | 4,330,891 | |||
Exercise of stock options, Shares | 686,432 | 686,432 | ||||
Common stock - restricted stock units vesting, Amount | $ 955 | (955) | ||||
Common stock - restricted stock units vesting, Shares | 955,404 | |||||
Common stock - issued for cash, Amount | $ 250,478,974 | $ 4,600 | 250,474,374 | |||
Common stock - issued for cash, Shares | 4,600,000 | |||||
Foreign currency translation adjustments | (237,490) | (237,490) | ||||
Net income (loss) | (22,509,298) | (22,509,298) | ||||
Ending Balance, Amount at Mar. 31, 2020 | 493,563,470 | $ 194,117 | 936,353,920 | (629,114) | (441,800,265) | (555,188) |
Ending Balance, Shares at Mar. 31, 2020 | 101,748,107 | |||||
Beginning Balance, Amount at Dec. 31, 2019 | 499,528,643 | $ 193,481 | 922,050,595 | (195,550) | (421,964,695) | (555,188) |
Beginning Balance, Shares at Dec. 31, 2019 | 101,111,797 | |||||
Stock-based compensation | 12,971,702 | 12,971,702 | ||||
Exercise of stock options, Amount | 1,330,024 | $ 214 | 1,329,810 | |||
Exercise of stock options, Shares | 214,239 | |||||
Common stock - restricted stock units vesting, Amount | $ 422 | (422) | ||||
Common stock - restricted stock units vesting, Shares | 422,071 | |||||
Common stock - issued for cash, Amount | 2,235 | 2,235 | ||||
Foreign currency translation adjustments | (433,564) | (433,564) | ||||
Net income (loss) | (19,835,570) | (19,835,570) | ||||
Ending Balance, Amount at Mar. 31, 2020 | $ 493,563,470 | $ 194,117 | $ 936,353,920 | $ (629,114) | $ (441,800,265) | $ (555,188) |
Ending Balance, Shares at Mar. 31, 2020 | 101,748,107 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 6 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net income (loss) | $ (22,509,298) | $ 35,934,235 |
Stock-based compensation | 17,463,455 | 5,318,882 |
Depreciation and amortization | 2,631,472 | 2,353,319 |
Amortization/(accretion) of note premiums | 419,212 | 330,229 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (604,410) | (13,094,965) |
Prepaid expenses and other current assets | 46,520 | (1,440,287) |
Deferred revenue | (49,630,006) | 120,622,138 |
Accounts payable | 5,767,770 | 1,256,092 |
Accrued expenses | (5,424,591) | (2,340,651) |
Other | 725,481 | (240,737) |
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES | (51,114,395) | 148,698,255 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Purchases of property and equipment | (7,929,100) | (946,788) |
Purchases of marketable securities | (180,523,424) | (90,266,001) |
Proceeds from sale of marketable securities | 19,602,967 | 12,239,219 |
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | (168,849,557) | (78,973,570) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Principal payments on notes payable | (2,415,150) | |
Proceeds from the exercises of stock options | 4,331,577 | 3,674,731 |
Proceeds from the issuance of common stock | 250,478,974 | 60,521,729 |
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES | 254,810,551 | 61,781,310 |
NET INCREASE (DECREASE) IN CASH | 34,846,599 | 131,505,995 |
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 221,804,128 | 30,133,213 |
CASH AND CASH EQUIVALENTS AT END OF PERIOD | $ 256,650,727 | 161,639,208 |
Supplementary disclosures: | ||
Interest paid | (27,437) | |
Income Taxes Paid | $ (2,400) |
Organization and Significant Ac
Organization and Significant Accounting Policies | 6 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Organization and Significant Accounting Policies | NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Nature of Business and Recent Developments Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company's pipeline includes ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (AATD), ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, and ARO-LUNG2 as a candidate to treat chronic obstructive pulmonary disease (COPD). ARO -JNJ1 is being developed for an undisclosed liver-expressed target under a collaboration agreement with Janssen Pharmaceuticals, Inc. (“Janssen”). ARO-HBV (JNJ-3989) for chronic hepatitis B virus was out-licensed to Janssen in October 2018. ARO-LPA (AMG 890) for cardiovascular disease was out-licensed to Amgen Inc. (“Amgen”) in 2016. Arrowhead operates a lab facility in Madison, Wisconsin, where the Company’s research and development activities, including the development of RNAi therapeutics, are based. The Company’s principal executive offices are located in Pasadena, California. During the three months ended March 31, 2020, the Company entered into a sublease for additional research and development facility space in San Diego, California as discussed further in Note 8 below. During the first half of fiscal 2020, the Company has continued to develop its pipeline and partnered candidates. The Company has began dosing in an adaptive design phase 2/3 trial, called SEQUOIA, with the potential to serve as a pivotal registration study of ARO-AAT. The Company also began dosing in its ARO-AAT 2002 study, a pilot open-label, multi-dose Phase 2 study to assess changes in novel histological activity scale in response to ARO-AAT over time in patients with alpha-1 antitrypsin deficiency associated liver disease. The Company also presented new clinical data on its two cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, in two late-breaking oral presentations at the American Heart Association Scientific Sessions 2019. The Company also filed an IND to begin a phase 1b study of ARO-HIF2, filed a CTA to begin a phase 1 study of ARO-HSD, and filed a CTA to begin a phase 1 study of ARO-ENaC. The Company’s partnered candidates under its collaboration agreements with Janssen and Amgen also continue to progress. Janssen began dosing patients in a phase 2b triple combination study called REEF-1, designed to enroll up to 450 patients with chronic hepatitis B infection, and in connection with the start of this study Arrowhead earned a $25 million milestone payment under the License Agreement (“Janssen License Agreement”). Janssen has also nominated the first of 3 potential candidates under the Research Collaboration and Option Agreement (“Janssen Collaboration Agreement”), ARO-JNJ1, and the Company is currently performing discovery, optimization and preclinical research and development for this candidate. (the “Second Collaboration and License Agreement” or “AMG 890 (ARO-LPA) Agreement”), The revenue recognition for these collaboration agreements is discussed further in Note 2 below. The Company is actively monitoring the novel coronavirus (“COVID-19”) situation. The financial results for the three and six months ended March 31, 2020 were not significantly impacted by COVID-19. The Company has paused enrollment in its two ARO-AAT studies: SEQUOIA and the ARO-AAT 2002 study, but now is working with sites and investigators to begin the process of resuming screening and enrollment. Patients already enrolled in these studies continue to be dosed per protocol and continue to come in for their follow up visits. Additional delays have occurred in the Company’s earlier stage programs, but we do not expect a material impact to any program’s anticipated timelines. Additionally, the Company’s operations at its research and development facility in Madison, WI and its corporate headquarters in Pasadena, CA have continued to operate with limited impact, other than for enhanced safety measures including work from home policies. Liquidity The Consolidated Financial Statements have been prepared in conformity with the accounting principles generally accepted in the United States of America, which contemplate the continuation of the Company as a going concern. Historically, the Company’s primary source of financing has been through the sale of its securities. Research and development activities have required significant capital investment since the Company’s inception. The Company expects its operations to continue to require cash investment to pursue its research and development goals, including clinical trials and related drug manufacturing. At March 31, 2020 the Company had $256.7 million in cash and cash equivalents (including $1.8 million in restricted cash), $51.0 million in short-term investments, and $190.6 million in long-term investments to fund operations. During the six months ended March 31, 2020, the Company’s cash and investments balance increased by $ 195.4 Summary of Significant Accounting Policies There have been no changes to the significant accounting policies disclosed in the Company’s most recent Annual Report on Form 10-K, except as a result of the Financial Accounting Standards Board (FASB)’s Accounting Standards Update (ASU) No. 2016-02, Leases (ASC 842), as discussed below. Leases — The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. Recent Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842). Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases). The Company adopted this standard effective October 1, 2019 and elected the package of three practical expedients that permits an entity to a) not reassess whether expired or existing contracts contain leases, b) not reassess lease classification for existing or expired leases, and c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. At March 31, 2020, the Company has recorded right-of-use assets of $10.3 million and right-of-use liabilities of $14.9 million on its Consolidated Balance Sheets for its research and development facility lease in Madison, Wisconsin, and its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below. The adoption of this standard did not have a material impact on the Company’s Consolidated Statement of Comprehensive Income (Loss) and the Company’s Consolidated Statement of Cash Flows. In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808). This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 becomes effective for the Company in the first quarter of fiscal 2021 with early adoption permitted. The Company does not expect the adoption of this update to have a material effect on its Consolidated Financial Statements. |
Collaboration and License Agree
Collaboration and License Agreements | 6 Months Ended |
Mar. 31, 2020 | |
Collaboration And License Agreements [Abstract] | |
Collaboration and License Agreements | NOTE 2. COLLABORATION AND LICENSE AGREEMENTS Amgen Inc. On September 28, 2016, the Company entered into two Collaboration and License agreements, and a Common Stock Purchase Agreement with Amgen Inc., a Delaware corporation (“Amgen”). Under one of the license agreements (the “Second Collaboration and License Agreement” or “AMG 890 (ARO-LPA) Agreement”), Amgen has received a worldwide, exclusive license to Arrowhead’s novel, RNAi ARO-LPA program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the other license agreement (the “First Collaboration and License Agreement” or “ARO-AMG1 Agreement”), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company’s Common Stock, and a $10 million milestone payment, and may receive up to $420 million in development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the AMG 890 (ARO-LPA) Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement. The Company substantially completed its performance obligations under the AMG 890 (ARO-LPA) Agreement and the ARO-AMG1 Agreement. Future milestones and royalties achieved will be recognized in their entirety when earned. During the three and six months ended March 31, 2020 and 2019, the Company recognized $0 and $0.3 million of Revenue associated with its agreements with Amgen, respectively. As of March 31, 2020, there were $0 contract assets recorded as accounts receivable, and $0 contract liabilities recorded as current deferred revenue on the Company’s Consolidated Balance Sheets. Janssen Pharmaceuticals, Inc. On October 3, 2018, the Company entered into a License Agreement (“Janssen License Agreement”) and a Research Collaboration and Option Agreement (“Janssen Collaboration Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen”) part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Company also entered into a Stock Purchase Agreement (“JJDC Stock Purchase Agreement”) with Johnson & Johnson Innovation-JJDC, Inc. (“JJDC”), a New Jersey corporation. Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company’s JNJ-3989 (ARO-HBV) program, the Company’s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potentially curative therapy for patients with chronic hepatitis B virus infection. Beyond the Company’s ongoing Phase 1 / 2 study of JNJ-3989 (ARO-HBV), Janssen will be wholly responsible for clinical development and commercialization. Under the Janssen Collaboration Agreement, Janssen will be able to select three new targets against which Arrowhead will develop clinical candidates. These candidates are subject to certain restrictions and will not include candidates in the Company’s current pipeline. The Company will perform discovery, optimization and preclinical research and development, entirely funded by Janssen, sufficient to allow the filing of a U.S. Investigational New Drug application or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $175 million as an upfront payment, $75 million in the form of an equity investment by JJDC in Arrowhead common stock under the JJDC The Company has evaluated these agreements in accordance with the new revenue recognition standard that became effective for the Company on October 1, 2018. The adoption of the new revenue standard did not have a material impact on the balances reported when evaluated under the superseded revenue standard. At the inception of these agreements, the Company has identified one distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&D services including the Company’s responsibility to complete the ongoing Phase 1 / 2 study of JNJ-3989 (ARO-HBV) and the Company’s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the “Janssen R&D Services”). Due to the specialized and unique nature of these Janssen R&D services, and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and thus, one performance obligation. The Company also determined that Janssen’s option to require the Company to develop up to three new targets is not a material right, and thus, not a performance obligation at the onset of the agreement. The consideration for this option will be accounted for if and when it is exercised. The Company determined the transaction price totaled approximately $252.5 million which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, the two $25 million milestone payments earned and estimated payments for reimbursable Janssen R&D services to be performed. The Company has allocated the total $252.5 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&D Services. This revenue will be recognized using a proportional performance method (based on actual labor hours versus estimated total labor hours) beginning in October 2018 and ending as the Company’s efforts in overseeing the ongoing phase 1 / 2 clinical trial are completed. During the three months ended March 31, 2020 and 2019, the Company recognized approximately $22.2 million and $47.9 million of Revenue associated with its agreements with Janssen and JJDC, respectively. Janssen has also selected the first of the three targets under the Janssen Collaboration Agreement, now referred to as ARO-JNJ1, and the Company has begun to conduct its discovery, optimization and preclinical research and development of ARO-JNJ1. All costs and labor hours spent by the Company will be entirely funded by Janssen. During the three months ended March 31, 2020 and 2019, the Company recognized approximately $1.4 million and $0 of Revenue associated with its efforts on the ARO-JNJ1 candidate, respectively. During the six months ended March 31, 2020 and 2019, the Company recognized $2.1 million and $0 of Revenue associated with these efforts on the ARO-JNJ1 candidate, respectively. As of March 31, 2020, there were $1.3 million of cont ract assets recorded as accounts t deferred revenue on the Company’s Consolidated Balance |
Property and Equipment
Property and Equipment | 6 Months Ended |
Mar. 31, 2020 | |
Property Plant And Equipment [Abstract] | |
Property and Equipment | NOTE 3. PROPERTY AND EQUIPMENT The following table summarizes the Company’s major classes of property and equipment: March 31, 2020 September 30, 2019 Computers, office equipment and furniture $ 635,769 $ 637,577 Research equipment 18,098,960 12,932,304 Software 293,189 147,254 Leasehold improvements 24,187,465 21,579,415 Total gross fixed assets 43,215,383 35,296,550 Less: Accumulated depreciation and amortization (13,852,642 ) (12,081,651 ) Property and equipment, net $ 29,362,741 $ 23,214,899 Depreciation and amortization expense for property and equipment for the three months ended March 31, 2020 and 2019 was $946,481 and $750,860, respectively. Depreciation and amortization expense for property and equipment for the six months ended March 31, 2020 and 2019 was $1,781,258 and $1,503,105, respectively. |
Investments
Investments | 6 Months Ended |
Mar. 31, 2020 | |
Held To Maturity Securities Classified [Abstract] | |
Investments | NOTE 4. INVESTMENTS The Company invests a portion of its excess cash balances in short-term and long-term debt securities. Investments at March 31, 2020 consisted of corporate bonds with maturities remaining of less than or equal to 36 months. The Company may also invest excess cash balances in certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investments in accordance with FASB ASC 320, Investments – Debt and Equity Securities. At March 31, 2020, all investments were classified as held-to-maturity securities. The following tables summarize the Company’s short-term and long-term investments as of March 31, 2020, and September 30, 2019. As of March 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Commercial notes (due within one year) $ 50,959,058 $ 264,194 $ (37,786) $ 51,185,466 Commercial notes (due within one through three years) $ 190,618,075 $ 1,735,812 $ (1,481,115) $ 190,872,772 Total $ 241,577,133 $ 2,000,006 $ (1,518,901) $ 242,058,238 As of September 30, 2019 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Commercial notes (due within one year) $ 36,899,894 $ 222,584 $ — $ 37,122,478 Commercial notes (due within one through three years) $ 44,175,993 $ 875,258 $ — $ 45,051,251 Total $ 81,075,887 $ 1,097,842 $ — $ 82,173,729 |
Intangible Assets
Intangible Assets | 6 Months Ended |
Mar. 31, 2020 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Intangible Assets | NOTE 5. INTANGIBLE ASSETS Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was 21 years, and the accumulated amortization of the asset is approximately $754,394. The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was 14 years, and the accumulated amortization of the assets is approximately $7,889,455. Amortization expense for the three months ended March 31, 2020 and 2019 was $425,107 and $425,108, respectively. Amortization expense for the six months ended March 31, 2020 and 2019 was $850,214 and $850,215, respectively. Amortization expense is expected to be $850,215 for the remainder of fiscal 2020, $1,700,429 in 2021, $1,700,429 in 2022, $1,700,429 in 2023, $1,700,429 in 2024, and $8,561,435 thereafter. The following table provides details on the Company’s intangible asset balances: Intangible assets subject to amortization Balance at September 30, 2019 $ 17,063,580 Impairment — Amortization (850,214 ) Balance at March 31, 2020 $ 16,213,366 |
Stockholders' Equity
Stockholders' Equity | 6 Months Ended |
Mar. 31, 2020 | |
Equity [Abstract] | |
Stockholders' Equity | NOTE 6. STOCKHOLDERS’ EQUITY At March 31, 2020, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. At March 31, 2020, 101,748,107 In December 31, 2019 the Company sold 4,600,000 shares of its Common Stock in a public offering at a price of $58.00 per share. The aggregate purchase price paid by the investors for the Common Stock was $266.8 million, and the Company received net proceeds of $250.5 million after deducting advisory fees and offering expenses. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Mar. 31, 2020 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | NOTE 7. COMMITMENTS AND CONTINGENCIES Litigation On occasion, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of March 31, 2020. Purchase Commitments In the normal course of business, the Company enters into various purchase commitments for the manufacture of drug components, for toxicology studies, and for clinical studies. As of March 31, 2020, these future commitments were estimated at approximately $72.2 million, of which approximately $40.0 million is expected to be incurred in fiscal 2020, and $32.2 million is expected to be incurred beyond fiscal 2020. Technology License Commitments The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and upon certain sales level milestones. These milestone payments could amount to the mid to upper double-digit millions of dollars. During the three and six months ended March 31, 2020, the Company accrued a $0.9 |
Leases
Leases | 6 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
Leases | NOTE 8. LEASES Leases In April 2019, the Company entered a new lease for its corporate headquarters in Pasadena, California. The 91 month office building lease between the Company and 177 Colorado Owner, LLC is for approximately 24,000 square feet of office space located at 177 E. Colorado Blvd, Pasadena, California, and this lease has replaced the Company’s previous corporate headquarters office lease. The increased capacity of this new office space compared to the Company’s current corporate headquarters will accommodate increased personnel as the Company’s pipeline of drug candidates expands and moves closer to market. Lease payments began on September 30, 2019 and are estimated to total approximately $8.8 million over the term. The Company also leases approximately 74,000 square feet of office and laboratory space for its research facility in Madison, Wisconsin. The lease will expire in September 2029. Lease payments are estimated to total approximately $13.3 million for the term. The lease contains two options to renew for two terms of five years. The exercise of these options were not determined to be reasonably certain and thus was not included in lease liabilities on the Company’s Consolidated Balance Sheet at March 31, 2020. Operating lease cost during the three and six months ended March 31, 2020 was $0.5 million and $0.9 million, respectively. Variable lease costs during the three and six months ended March 31, 2020 were $0.2 million and $0.3 million, respectively. There was no short-term lease cost during the three and six months ended March 31, 2020. The following table presents maturities of operating lease liabilities on an undiscounted basis as of March 31, 2020: 2020 (remainder of fiscal year) $ 936,566 2021 2,256,379 2022 2,521,446 2023 2,590,558 2024 2,661,512 2025 and thereafter 10,834,206 Total lease payments 21,800,667 Less imputed interest (6,933,478) Total operating lease liabilities (includes current portion) $ 14,867,189 Cash paid for the amounts included in the measurement of the operating lease liabilities on the Company’s Consolidated Balance Sheet and included in Other changes in operating assets and liabilities within cash flows from operating activities on the Company’s Consolidated Statement of Cash Flow for the three and six months ended March 31, 2020 was $0.3 million and $0.6 million, respectively. The weighted-average remaining lease term and weighted-average discount rate for all leases as of March 31, 2020 was 8.6 years and 8.9%, respectively. As of September 30, 2019, future minimum lease payments due in fiscal years under operating leases were as follows: 2020 $ 1,521,451 2021 2,256,379 2022 2,521,446 2023 2,590,558 2024 2,661,512 2025 and thereafter 10,834,206 Total $ 22,385,552 During the three months ended March 31, 2020, the Company entered into a sublease agreement (the “Sublease”) with Halozyme, Inc. for additional research and development facility space in San Diego, California. The Sublease provides additional space needed to accommodate the recent growth of the Company’s personnel and discovery efforts. The space consists of approximately 21,000 rentable square feet located at 11404 Sorento Valley Road, San Diego, California, 92121. The term of the Sublease commenced on April 1, 2020 and will expire on January 14, 2023. Lease payments are estimated to total approximately $2.1 million over the term. |
Stock-Based Compensation
Stock-Based Compensation | 6 Months Ended |
Mar. 31, 2020 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Stock-Based Compensation | NOTE 9. STOCK-BASED COMPENSATION Arrowhead has two plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and 2013 Incentive Plan, as of March 31, 2020, 886,598 and 5,972,038 shares, respectively, of Arrowhead’s Common Stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others. No further grants may be made under the 2004 Equity Incentive Plan. As of March 31, 2020, there were options granted and outstanding to purchase 886,598 and 2,798,538 shares of Common Stock under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively, and there were 2,783,000 restricted stock units granted and outstanding under the 2013 Incentive Plan. Also, as of March 31, 2020, there were 1,024,850 shares reserved for options and 591,075 shares reserved for restricted stock units issued as inducement grants to new employees outside of equity compensation plans. During the three months ended March 31, 2020, 306,500 options and 1,744,071 restricted stock units were granted under the 2013 Incentive Plan, and 126,000 options and 300,000 restricted stock units were granted as inducement awards to new employees outside of equity incentive plans. During the six months ended March 31, 2020, 310,500 options and 1,749,071 restricted stock units were granted under the 2013 Incentive Plan, and 343,000 options and 584,575 restricted stock units were granted as inducement awards to new employees outside of the equity incentive plans. The following table summarizes information about stock options: Number of Options Outstanding Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Balance At September 30, 2019 4,773,670 $ 8.16 Granted 653,500 53.78 Cancelled (30,752 ) 15.00 Exercised (686,432 ) 6.31 Balance At March 31, 2020 4,709,986 $ 14.72 6.2 years $ 82,658,407 Exercisable At March 31, 2020 3,111,009 $ 7.12 4.8 years $ 67,796,517 Stock-based compensation expense related to stock options for the three months ended March 31, 2020 and 2019 was $2,527,839 and $1,017,065, respectively. Stock-based compensation expense related to stock options for the six months ended March 31, 2020 and 2019 was $4,136,910 and $1,807,500, respectively. For non-qualified stock options, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. The grant date fair value of the options granted by the Company for the three months ended March 31, 2020 and 2019 was $17,968,884 and $7,580,360, respectively. The grant date fair value of the options granted by the Company for the six months ended March 31, 2020 and 2019 was $26,599,374 and $8,137,249, respectively. The intrinsic value of the options exercised during the three months ended March 31, 2020 and 2019 was $8,605,235 and $6,806,594, respectively. The intrinsic value of the options exercised during the six months ended March 31, 2020 and 2019 was $30,245,825 and $8,122,294, respectively. As of March 31, 2020, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $34,707,355 will be recognized in the Company’s results of operations over a weighted average period of 3.5 The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company’s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. The assumptions used to value stock options are as follows: Six Months Ended March 31, 2020 2019 Dividend yield — — Risk-free interest rate 0.5 – 1.8% 2.3 – 3.1% Volatility 90.5 – 91.8% 115% Expected life (in years) 6.25 6.25 Weighted average grant date fair value per share of options granted $40.70 $11.42 The dividend yield is zero as the Company currently does not pay a dividend. The risk-free interest rate is based on that of the U.S. Treasury bond. Volatility is estimated based on volatility average of the Company’s Common Stock price. Restricted Stock Units Restricted stock units (RSUs), including time-based and performance-based awards, were granted under the Company’s 2013 Incentive Plan and as inducements grants granted outside of the Plan. During the three months ended March 31, 2020, the Company issued 1,744,071 RSUs under the 2013 Incentive Plan and 300,000 RSUs as inducement awards. During the six months ended March 31, 2020, the Company issued 1,749,071 RSUs under the 2013 Incentive Plan and 584,575 RSUs as inducement awards. At vesting, each outstanding RSU will be exchanged for one share of the Company’s Common Stock. RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee’s income taxes due upon vesting and withholds a number of shares of Common Stock of equal value. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets. The following table summarizes the activity of the Company’s RSUs: Number of RSUs Weighted- Average Grant Date Fair Value Unvested at September 30, 2019 2,062,833 $ 9.43 Granted 2,333,646 58.27 Vested (955,404 ) 9.07 Forfeited (67,000 ) 31.78 Unvested at March 31, 2020 3,374,075 $ 42.87 During the three months ended March 31, 2020 and 2019, the Company recorded $10,443,863 and $1,584,283 of expense related to RSUs, respectively. During the six months ended March 31, 2020 and 2019, the Company recorded $13,326,545 and $3,511,381 of expense related to RSUs, respectively. Such expense is included in stock-based compensation expense in the Company’s Consolidated Statement of Operations and Comprehensive Income (Loss). For RSUs, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. For RSUs, the grant date fair value of the award is based on the Company’s closing stock price at the grant date, with consideration given to the probability of achieving performance conditions for performance-based awards. As of March 31, 2020 the pre-tax compensation expense for all unvested RSUs in the amount of $89,156,048 will be recognized in the Company’s results of operations over a weighted average period of 3.5 years. |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Mar. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | NOTE 10. FAIR VALUE MEASUREMENTS The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level 1 provides the most reliable measure of fair value while Level 3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: Level 1—Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. Level 2—Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. Level 3—Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management’s best estimate of what market participants would use in valuing the asset or liability at the measurement date. The following table summarizes fair value measurements at March 31, 2020 and September 30, 2019 for assets and liabilities measured at fair value on a recurring basis: March 31, 2020: Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 256,650,727 $ — $ — $ 256,650,727 Short-term investments $ 51,185,466 $ — $ — $ 51,185,466 Long-term investments $ 190,872,772 $ — $ — $ 190,872,772 Contingent consideration $ — $ — $ — $ — September 30, 2019 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 221,804,128 $ — $ — $ 221,804,128 Short-term investments $ 37,122,478 $ — $ — $ 37,122,478 Long-term investments $ 45,051,251 $ — $ — $ 45,051,251 Contingent consideration $ — $ — $ — $ — The Company had a liability for contingent consideration related to its acquisition of the Roche RNAi business completed in 2011. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company’s assumptions and experience. Estimating timing to complete the development and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining FDA and other regulatory approvals. In determining the probability of regulatory approval and commercial success, the Company utilizes data regarding similar milestone events from several sources, including industry studies and its own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. In November 2016, the Company announced the discontinuation of its clinical trial efforts for ARC-520, ARC-AAT and ARC-521. Given this development, the Company assessed the fair value of its contingent consideration obligation to be $0 at March 31, 2020 and September 30, 2019. |
Organization and Significant _2
Organization and Significant Accounting Policies (Policies) | 6 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Leases | Leases — The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842). Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases). The Company adopted this standard effective October 1, 2019 and elected the package of three practical expedients that permits an entity to a) not reassess whether expired or existing contracts contain leases, b) not reassess lease classification for existing or expired leases, and c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. At March 31, 2020, the Company has recorded right-of-use assets of $10.3 million and right-of-use liabilities of $14.9 million on its Consolidated Balance Sheets for its research and development facility lease in Madison, Wisconsin, and its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below. The adoption of this standard did not have a material impact on the Company’s Consolidated Statement of Comprehensive Income (Loss) and the Company’s Consolidated Statement of Cash Flows. In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808). This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 becomes effective for the Company in the first quarter of fiscal 2021 with early adoption permitted. The Company does not expect the adoption of this update to have a material effect on its Consolidated Financial Statements. |
Property and Equipment (Tables)
Property and Equipment (Tables) | 6 Months Ended |
Mar. 31, 2020 | |
Property Plant And Equipment [Abstract] | |
Summary of Property and Equipment | The following table summarizes the Company’s major classes of property and equipment: March 31, 2020 September 30, 2019 Computers, office equipment and furniture $ 635,769 $ 637,577 Research equipment 18,098,960 12,932,304 Software 293,189 147,254 Leasehold improvements 24,187,465 21,579,415 Total gross fixed assets 43,215,383 35,296,550 Less: Accumulated depreciation and amortization (13,852,642 ) (12,081,651 ) Property and equipment, net $ 29,362,741 $ 23,214,899 |
Investments (Tables)
Investments (Tables) | 6 Months Ended |
Mar. 31, 2020 | |
Held To Maturity Securities Classified [Abstract] | |
Summary of Short-term and Long-term Investments | The following tables summarize the Company’s short-term and long-term investments as of March 31, 2020, and September 30, 2019. As of March 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Commercial notes (due within one year) $ 50,959,058 $ 264,194 $ (37,786) $ 51,185,466 Commercial notes (due within one through three years) $ 190,618,075 $ 1,735,812 $ (1,481,115) $ 190,872,772 Total $ 241,577,133 $ 2,000,006 $ (1,518,901) $ 242,058,238 As of September 30, 2019 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Commercial notes (due within one year) $ 36,899,894 $ 222,584 $ — $ 37,122,478 Commercial notes (due within one through three years) $ 44,175,993 $ 875,258 $ — $ 45,051,251 Total $ 81,075,887 $ 1,097,842 $ — $ 82,173,729 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 6 Months Ended |
Mar. 31, 2020 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets | The following table provides details on the Company’s intangible asset balances: Intangible assets subject to amortization Balance at September 30, 2019 $ 17,063,580 Impairment — Amortization (850,214 ) Balance at March 31, 2020 $ 16,213,366 |
Leases (Tables)
Leases (Tables) | 6 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis | The following table presents maturities of operating lease liabilities on an undiscounted basis as of March 31, 2020: 2020 (remainder of fiscal year) $ 936,566 2021 2,256,379 2022 2,521,446 2023 2,590,558 2024 2,661,512 2025 and thereafter 10,834,206 Total lease payments 21,800,667 Less imputed interest (6,933,478) Total operating lease liabilities (includes current portion) $ 14,867,189 |
Future Minimum Lease Payments Under Operating Leases | As of September 30, 2019, future minimum lease payments due in fiscal years under operating leases were as follows: 2020 $ 1,521,451 2021 2,256,379 2022 2,521,446 2023 2,590,558 2024 2,661,512 2025 and thereafter 10,834,206 Total $ 22,385,552 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 6 Months Ended |
Mar. 31, 2020 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Summarized Information about Stock Options | The following table summarizes information about stock options: Number of Options Outstanding Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Balance At September 30, 2019 4,773,670 $ 8.16 Granted 653,500 53.78 Cancelled (30,752 ) 15.00 Exercised (686,432 ) 6.31 Balance At March 31, 2020 4,709,986 $ 14.72 6.2 years $ 82,658,407 Exercisable At March 31, 2020 3,111,009 $ 7.12 4.8 years $ 67,796,517 |
Assumptions Used to Value Stock Options | The assumptions used to value stock options are as follows: Six Months Ended March 31, 2020 2019 Dividend yield — — Risk-free interest rate 0.5 – 1.8% 2.3 – 3.1% Volatility 90.5 – 91.8% 115% Expected life (in years) 6.25 6.25 Weighted average grant date fair value per share of options granted $40.70 $11.42 |
Summary of Share Activity Related to RSUs | The following table summarizes the activity of the Company’s RSUs: Number of RSUs Weighted- Average Grant Date Fair Value Unvested at September 30, 2019 2,062,833 $ 9.43 Granted 2,333,646 58.27 Vested (955,404 ) 9.07 Forfeited (67,000 ) 31.78 Unvested at March 31, 2020 3,374,075 $ 42.87 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Mar. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis | The following table summarizes fair value measurements at March 31, 2020 and September 30, 2019 for assets and liabilities measured at fair value on a recurring basis: March 31, 2020: Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 256,650,727 $ — $ — $ 256,650,727 Short-term investments $ 51,185,466 $ — $ — $ 51,185,466 Long-term investments $ 190,872,772 $ — $ — $ 190,872,772 Contingent consideration $ — $ — $ — $ — September 30, 2019 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 221,804,128 $ — $ — $ 221,804,128 Short-term investments $ 37,122,478 $ — $ — $ 37,122,478 Long-term investments $ 45,051,251 $ — $ — $ 45,051,251 Contingent consideration $ — $ — $ — $ — |
Organization and Significant _3
Organization and Significant Accounting Policies - Additional Information (Detail) | Oct. 03, 2018USD ($)Target | Sep. 28, 2016USD ($) | Dec. 31, 2019USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Sep. 30, 2019USD ($) |
Organization And Significant Accounting Policies [Line Items] | ||||||
Proceeds from the issuance of common stock | $ 250,500,000 | $ 250,478,974 | $ 60,521,729 | |||
Cash and cash equivalents | 256,650,727 | $ 221,804,128 | ||||
Restricted Cash | 1,800,000 | |||||
Short term investments | 50,959,058 | 36,899,894 | ||||
Long term investments | 190,618,075 | $ 44,175,993 | ||||
Net increase (decrease) in cash and investments | 195,400,000 | |||||
Right-of-use assets | 10,263,197 | |||||
Right-of-use liabilities | 14,867,189 | |||||
Janssen | JNJ-3989 (ARO-HBV) Agreement | ||||||
Organization And Significant Accounting Policies [Line Items] | ||||||
Milestone payment | $ 25,000,000 | 25,000,000 | ||||
Janssen | Collaboration Agreement | ||||||
Organization And Significant Accounting Policies [Line Items] | ||||||
Number of additional targets for development and sales milestone payments | Target | 3 | |||||
Janssen and JJDC | Collaboration and License agreements | ||||||
Organization And Significant Accounting Policies [Line Items] | ||||||
Cash received as due under agreement | $ 175,000,000 | |||||
JJDC | Common Stock Purchase Agreement | ||||||
Organization And Significant Accounting Policies [Line Items] | ||||||
Proceeds from the issuance of common stock | 75,000,000 | |||||
Amgen | License Collaboration and Stock Purchase Agreement | ||||||
Organization And Significant Accounting Policies [Line Items] | ||||||
Cash received as due under agreement | $ 35,000,000 | |||||
Proceeds from the issuance of common stock | 21,500,000 | |||||
Amgen | AMG-890 (ARO-LPA) Agreement | ||||||
Organization And Significant Accounting Policies [Line Items] | ||||||
Milestone payment | $ 10,000,000 | |||||
Maximum | Janssen | License Agreement | ||||||
Organization And Significant Accounting Policies [Line Items] | ||||||
Development regulatory and sales milestones payments | 1,600,000,000 | |||||
Maximum | Janssen | Collaboration Agreement | ||||||
Organization And Significant Accounting Policies [Line Items] | ||||||
Development regulatory and sales milestones payments | $ 1,900,000,000 | |||||
Maximum | Amgen | AMG-890 (ARO-LPA) Agreement | ||||||
Organization And Significant Accounting Policies [Line Items] | ||||||
Development regulatory and sales milestones payments | $ 420,000,000 |
Collaboration and License Agr_2
Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail) | Sep. 28, 2016USD ($)Agreement | Dec. 31, 2019USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Sep. 30, 2019USD ($) |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Proceeds from the issuance of common stock | $ 250,500,000 | $ 250,478,974 | $ 60,521,729 | ||||
Revenues | $ 23,528,853 | $ 48,148,275 | 52,983,433 | $ 82,806,171 | |||
Contract liabilities | $ 33,174,765 | $ 33,174,765 | $ 77,769,629 | ||||
Type of Revenue [Extensible List] | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember | |||
Collaboration and License agreements | Amgen | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Agreement date | Sep. 28, 2016 | ||||||
Number of agreements | Agreement | 2 | ||||||
Cash received as due under collaboration agreement | $ 35,000,000 | ||||||
AMG-890 (ARO-LPA) Agreement | Amgen | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Milestone payment | 10,000,000 | ||||||
AMG-890 (ARO-LPA) Agreement | Amgen | Maximum | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Development regulatory and sales milestones payments | $ 420,000,000 | $ 420,000,000 | |||||
License Collaboration and Stock Purchase Agreement | Amgen | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Proceeds from the issuance of common stock | $ 21,500,000 | ||||||
AMG 890 (ARO-LPA) and ARO-AMG1 Agreement | Amgen | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Revenues | 0 | $ 300,000 | 0 | $ 300,000 | |||
Contract liabilities | 0 | 0 | |||||
Contract assets | $ 0 | $ 0 | |||||
Type of Revenue [Extensible List] | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember |
Collaboration and License Agr_3
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail) | Oct. 03, 2018USD ($)TargetObligation | Dec. 31, 2019USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Sep. 30, 2019USD ($) |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Proceeds from the issuance of common stock | $ 250,500,000 | $ 250,478,974 | $ 60,521,729 | ||||
Revenues | $ 23,528,853 | $ 48,148,275 | 52,983,433 | 82,806,171 | |||
Deferred revenue | 33,174,765 | 33,174,765 | $ 77,769,629 | ||||
Collaboration and License agreements | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Initial transaction price | $ 252,500,000 | ||||||
Janssen | License Agreement | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Agreement date | Oct. 3, 2018 | ||||||
Janssen | License Agreement | Maximum | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Development, regulatory and sales milestones payments | $ 1,600,000,000 | ||||||
Janssen | Research Collaboration and Option Agreement | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Agreement date | Oct. 3, 2018 | ||||||
Number of additional targets for development, regulatory and sales milestone payments | Target | 3 | ||||||
Janssen | Collaboration Agreement | Maximum | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Development, regulatory and sales milestones payments | $ 1,900,000,000 | ||||||
Janssen | JNJ-3989 (ARO-HBV) Agreement | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Milestone payment | $ 25,000,000 | 25,000,000 | 25,000,000 | ||||
Number of distinct performance obligations | Obligation | 1 | ||||||
Revenues | 22,200,000 | 47,900,000 | 50,900,000 | 82,500,000 | |||
Contract assets | 0 | 0 | |||||
Deferred revenue | 33,200,000 | 33,200,000 | |||||
Janssen | ARO-JNJ1 | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Revenues | 1,400,000 | $ 0 | 2,100,000 | $ 0 | |||
Contract assets | 1,300,000 | 1,300,000 | |||||
Deferred revenue | $ 0 | $ 0 | |||||
JJDC | Common Stock Purchase Agreement | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Agreement date | Oct. 3, 2018 | ||||||
Proceeds from the issuance of common stock | $ 75,000,000 | ||||||
Janssen and JJDC | Collaboration and License agreements | |||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||
Cash received as due under collaboration agreement | $ 175,000,000 |
Property and Equipment - Summar
Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) | Mar. 31, 2020 | Sep. 30, 2019 |
Property Plant And Equipment [Abstract] | ||
Computers, office equipment and furniture | $ 635,769 | $ 637,577 |
Research equipment | 18,098,960 | 12,932,304 |
Software | 293,189 | 147,254 |
Leasehold improvements | 24,187,465 | 21,579,415 |
Total gross fixed assets | 43,215,383 | 35,296,550 |
Less: Accumulated depreciation and amortization | (13,852,642) | (12,081,651) |
Property and equipment, net | $ 29,362,741 | $ 23,214,899 |
Property and Equipment - Additi
Property and Equipment - Additional Information (Detail) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | |
Property Plant And Equipment [Abstract] | ||||
Depreciation and amortization expense for property and equipment | $ 946,481 | $ 750,860 | $ 1,781,258 | $ 1,503,105 |
Investments - Summary of Short-
Investments - Summary of Short-term and Long-term Investments (Detail) - USD ($) | Mar. 31, 2020 | Sep. 30, 2019 |
Schedule Of Held To Maturity Securities [Line Items] | ||
Amortized Cost | $ 241,577,133 | $ 81,075,887 |
Gross Unrealized Gains | 2,000,006 | 1,097,842 |
Gross Unrealized Losses | (1,518,901) | |
Fair Value | 242,058,238 | 82,173,729 |
Commercial Notes Due Within One Year | ||
Schedule Of Held To Maturity Securities [Line Items] | ||
Amortized Cost | 50,959,058 | 36,899,894 |
Gross Unrealized Gains | 264,194 | 222,584 |
Gross Unrealized Losses | (37,786) | |
Fair Value | 51,185,466 | 37,122,478 |
Commercial Notes Due Within One Through Three Years | ||
Schedule Of Held To Maturity Securities [Line Items] | ||
Amortized Cost | 190,618,075 | 44,175,993 |
Gross Unrealized Gains | 1,735,812 | 875,258 |
Gross Unrealized Losses | (1,481,115) | |
Fair Value | $ 190,872,772 | $ 45,051,251 |
Intangible Assets - Additional
Intangible Assets - Additional Information (Detail) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | |
Finite Lived Intangible Assets [Line Items] | ||||
Amortization expense | $ 425,107 | $ 425,108 | $ 850,214 | $ 850,215 |
Amortization of license agreements remainder of fiscal year 2020 | 850,215 | 850,215 | ||
Amortization of license agreements in 2021 | 1,700,429 | 1,700,429 | ||
Amortization of license agreements in 2022 | 1,700,429 | 1,700,429 | ||
Amortization of license agreements in 2023 | 1,700,429 | 1,700,429 | ||
Amortization of license agreements in 2024 | 1,700,429 | 1,700,429 | ||
Amortization of license agreements, thereafter | 8,561,435 | $ 8,561,435 | ||
Novartis | Licensing Agreement | ||||
Finite Lived Intangible Assets [Line Items] | ||||
Amortization period of intangible assets | 21 years | |||
Finite-lived intangible assets, accumulated amortization | 754,394 | $ 754,394 | ||
Novartis | Patents | ||||
Finite Lived Intangible Assets [Line Items] | ||||
Amortization period of intangible assets | 14 years | |||
Finite-lived intangible assets, accumulated amortization | $ 7,889,455 | $ 7,889,455 |
Intangible Assets - Schedule of
Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | |
Intangible Assets Net Excluding Goodwill [Abstract] | ||||
Intangible assets subject to amortization, beginning balance | $ 17,063,580 | |||
Intangible assets subject to amortization, Amortization | $ (425,107) | $ (425,108) | (850,214) | $ (850,215) |
Intangible assets subject to amortization, ending balance | $ 16,213,366 | $ 16,213,366 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Detail) - USD ($) | 1 Months Ended | 6 Months Ended | ||
Dec. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | Sep. 30, 2019 | |
Class Of Stock [Line Items] | ||||
Capital stock authorized for issuance | 150,000,000 | |||
Common stock, shares authorized | 145,000,000 | 145,000,000 | ||
Common stock, par value | $ 0.001 | $ 0.001 | ||
Preferred stock, shares authorized | 5,000,000 | |||
Preferred stock, par value | $ 0.001 | |||
Common stock, shares outstanding | 101,748,107 | 95,506,271 | ||
Net proceeds from common stock after deducting advisory fees and offering expenses | $ 250,500,000 | $ 250,478,974 | $ 60,521,729 | |
Public Offering | ||||
Class Of Stock [Line Items] | ||||
Shares issued to institutional investors | 4,600,000 | |||
Aggregate purchase price paid by investors | $ 266,800,000 | |||
Net proceeds from common stock after deducting advisory fees and offering expenses | $ 250,500,000 | |||
Stock issued, price per share | $ 58 | |||
2004 Equity Incentive Plan, 2013 Equity Incentive Plan, and Inducement Grants | ||||
Class Of Stock [Line Items] | ||||
Common Stock, Share reserve for issuance | 8,474,561 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) - USD ($) | Mar. 31, 2020 | Mar. 31, 2019 |
Other Commitments [Line Items] | ||
Contingent liabilities | $ 0 | |
Future commitments | 72,200,000 | |
Commitments expected to be incurred in fiscal 2020 | 40,000,000 | |
Commitments expected to be incurred beyond fiscal 2020 | 32,200,000 | |
Technology License Commitments | ||
Other Commitments [Line Items] | ||
Accrued milestone payments | $ 0 | |
Technology License Commitments | ARO-ENaC Program | ||
Other Commitments [Line Items] | ||
Accrued milestone payments | $ 900,000 |
Leases - Additional Information
Leases - Additional Information (Detail) | 1 Months Ended | 3 Months Ended | 6 Months Ended | |
Apr. 30, 2019USD ($)ft²Option | Mar. 31, 2020USD ($)ft²Option | Mar. 31, 2020USD ($)ft²Option | Sep. 30, 2019USD ($) | |
Lessee Lease Description [Line Items] | ||||
Estimated lease payments | $ 22,385,552 | |||
Estimated lease payments | $ 21,800,667 | $ 21,800,667 | ||
Operating lease cost | 500,000 | 900,000 | ||
Variable lease cost | 200,000 | 300,000 | ||
Short-term lease cost | 0 | 0 | ||
Operating lease cash payments | $ 300,000 | $ 600,000 | ||
Weighted-average remaining lease term | 8 years 7 months 6 days | 8 years 7 months 6 days | ||
Weighted-average discount rate | 8.90% | 8.90% | ||
Research Facility in Madison | Wisconsin | ||||
Lessee Lease Description [Line Items] | ||||
Office space leases, in square feet | ft² | 74,000 | 74,000 | ||
Operating lease renewal term | 5 years | 5 years | ||
Number of options to renew | Option | 2 | 2 | ||
Operating lease expiration month and year | 2029-09 | |||
Estimated lease payments | $ 13,300,000 | $ 13,300,000 | ||
Colorado Owner, LLC | Corporate Headquarters In Pasadena | California | ||||
Lessee Lease Description [Line Items] | ||||
Lease term | 91 months | |||
Office space leases, in square feet | ft² | 24,000 | |||
Lease payments, commencement date | Sep. 30, 2019 | |||
Estimated lease payments | $ 8,800,000 | |||
Expected leasehold improvements, net of tenant improvement allowances | $ 3,500,000 | |||
Operating lease renewal term | 5 years | |||
Number of options to renew | Option | 1 | |||
Halozyme, Inc. | California | Sublease Agreement | ||||
Lessee Lease Description [Line Items] | ||||
Office space leases, in square feet | ft² | 21,000 | 21,000 | ||
Estimated lease payments | $ 2,100,000 | $ 2,100,000 | ||
Sublease commencement date | Apr. 1, 2020 | |||
Lease expiration date | Jan. 14, 2023 |
Leases - Summary of Maturities
Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail) | Mar. 31, 2020USD ($) |
Leases [Abstract] | |
2020 (remainder of fiscal year) | $ 936,566 |
2021 | 2,256,379 |
2022 | 2,521,446 |
2023 | 2,590,558 |
2024 | 2,661,512 |
2025 and thereafter | 10,834,206 |
Total lease payments | 21,800,667 |
Less imputed interest | (6,933,478) |
Total operating lease liabilities (includes current portion) | $ 14,867,189 |
Leases - Future Minimum Lease P
Leases - Future Minimum Lease Payments Under Operating Leases (Detail) | Sep. 30, 2019USD ($) |
Leases [Abstract] | |
2020 | $ 1,521,451 |
2021 | 2,256,379 |
2022 | 2,521,446 |
2023 | 2,590,558 |
2024 | 2,661,512 |
2025 and thereafter | 10,834,206 |
Total | $ 22,385,552 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional Information (Detail) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | Sep. 30, 2019 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Number of options outstanding | 4,709,986 | 4,709,986 | 4,773,670 | ||
Number of options outstanding, granted | 653,500 | ||||
RSU awards vesting, description | At vesting, each outstanding RSU will be exchanged for one share of the Company’s Common Stock. RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee’s income taxes due upon vesting and withholds a number of shares of Common Stock of equal value. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets. | ||||
Employee Stock Option | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Stock-based compensation expense | $ 2,527,839 | $ 1,017,065 | $ 4,136,910 | $ 1,807,500 | |
Grant date fair value of the options granted | 17,968,884 | 7,580,360 | 26,599,374 | 8,137,249 | |
Intrinsic value of options exercised | 8,605,235 | 6,806,594 | 30,245,825 | 8,122,294 | |
Unrecognized pre-tax compensation expense | 34,707,355 | $ 34,707,355 | |||
Weighted average period to recognize pre-tax compensation expense | 3 years 6 months | ||||
Dividend yield | 0.00% | ||||
Restricted Stock Units (RSUs) | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Number of restricted stock units outstanding, granted | 2,333,646 | ||||
Stock-based compensation expense | 10,443,863 | $ 1,584,283 | $ 13,326,545 | $ 3,511,381 | |
Weighted average period to recognize pre-tax compensation expense | 3 years 6 months | ||||
Unrecognized pre-tax compensation expense | $ 89,156,048 | $ 89,156,048 | |||
2004 Equity Incentive Plan | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Shares reserve for issuance | 886,598 | 886,598 | |||
2004 Equity Incentive Plan | Employee Stock Option | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Number of options outstanding | 886,598 | 886,598 | |||
2013 Incentive Plan | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Shares reserve for issuance | 5,972,038 | 5,972,038 | |||
2013 Incentive Plan | Employee Stock Option | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Number of options outstanding | 2,798,538 | 2,798,538 | |||
Number of options outstanding, granted | 306,500 | 310,500 | |||
2013 Incentive Plan | Restricted Stock Units (RSUs) | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Number of restricted stock units outstanding | 2,783,000 | 2,783,000 | |||
Number of restricted stock units outstanding, granted | 1,744,071 | 1,749,071 | |||
Outside Of Equity Compensation Plans | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Shares reserve for issuance | 1,024,850 | 1,024,850 | |||
Outside Of Equity Compensation Plans | Employee Stock Option | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Number of options outstanding, granted | 126,000 | 343,000 | |||
Outside Of Equity Compensation Plans | Restricted Stock Units (RSUs) | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Shares reserve for issuance | 591,075 | 591,075 | |||
Number of restricted stock units outstanding, granted | 300,000 | 584,575 |
Stock-Based Compensation - Summ
Stock-Based Compensation - Summarize Information about Stock Options (Detail) - USD ($) | 6 Months Ended |
Mar. 31, 2020 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Number of Options Outstanding, beginning balance | 4,773,670 |
Number of Options Outstanding, Granted | 653,500 |
Number of Options Outstanding, Cancelled | (30,752) |
Number of Options Outstanding, Exercised | (686,432) |
Number of Options Outstanding, ending balance | 4,709,986 |
Number of Options Outstanding, Exercisable | 3,111,009 |
Weighted-Average Exercise Price Per Share, beginning balance | $ 8.16 |
Weighted-Average Exercise Price Per Share, Granted | 53.78 |
Weighted-Average Exercise Price Per Share, Cancelled | 15 |
Weighted-Average Exercise Price Per Share, Exercised | 6.31 |
Weighted-Average Exercise Price Per Share, ending balance | 14.72 |
Weighted-Average Exercise Price Per Share, Exercisable | $ 7.12 |
Weighted-Average Remaining Contractual Term | 6 years 2 months 12 days |
Weighted-Average Remaining Contractual Term, Exercisable | 4 years 9 months 18 days |
Aggregate Intrinsic Value | $ 82,658,407 |
Aggregate Intrinsic Value, Exercisable | $ 67,796,517 |
Stock-Based Compensation - Assu
Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail) - $ / shares | 6 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract] | ||
Risk-free interest rate, minimum | 0.50% | 2.30% |
Risk-free interest rate, maximum | 1.80% | 3.10% |
Volatility | 115.00% | |
Volatility, minimum | 90.50% | |
Volatility, maximum | 91.80% | |
Expected life (in years) | 6 years 3 months | 6 years 3 months |
Weighted average grant date fair value per share of options granted | $ 40.70 | $ 11.42 |
Stock-Based Compensation - Su_2
Stock-Based Compensation - Summary of RSUs Activity (Detail) - Restricted Stock Units (RSUs) | 6 Months Ended |
Mar. 31, 2020$ / sharesshares | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Number of RSUs, Unvested, beginning of period | shares | 2,062,833 |
Number of RSUs, Granted | shares | 2,333,646 |
Number of RSUs, Vested | shares | (955,404) |
Number of RSUs, Forfeited | shares | (67,000) |
Number of RSUs, Unvested, End of period | shares | 3,374,075 |
Weighted-Average Grant Date Fair Value, beginning balance | $ / shares | $ 9.43 |
Weighted-Average Grant Date Fair Value, Granted | $ / shares | 58.27 |
Weighted-Average Grant Date Fair Value, Vested | $ / shares | 9.07 |
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares | 31.78 |
Weighted-Average Grant Date Fair Value, ending balance | $ / shares | $ 42.87 |
Fair Value Measurements - Fair
Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) | Mar. 31, 2020 | Sep. 30, 2019 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Short-term investments | $ 242,058,238 | $ 82,173,729 |
Contingent consideration | 0 | 0 |
Fair Value, Measurements, Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 256,650,727 | 221,804,128 |
Short-term investments | 51,185,466 | 37,122,478 |
Long-term investments | 190,872,772 | 45,051,251 |
Fair Value, Measurements, Recurring | Level 1 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 256,650,727 | 221,804,128 |
Short-term investments | 51,185,466 | 37,122,478 |
Long-term investments | $ 190,872,772 | $ 45,051,251 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Detail) - USD ($) | Mar. 31, 2020 | Sep. 30, 2019 |
Fair Value Disclosures [Abstract] | ||
Contingent consideration obligations | $ 0 | $ 0 |